A new study led by scientists at The Wistar Institute, in collaboration with the University of Pennsylvania Perelman School ...

Findings show potential for new lipid-based delivery formulations as a platform technology for immunizationPhiladelphia, PA, ...

A recently identified bacterial protein structure is contributing to the design of novel anticancer drug delivery systems.

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Shares of Prime Medicine (NASDAQ: PRME) are surging on Thursday. The move up comes as the S&P 500 and Nasdaq Composite gained ...

Immunotherapy has emerged as one of the major options for cancer treatment in the past decade. With the successful application of immune checkpoint inhibitors and the introduction of immune regulatory ...

Curia will expand its Glasgow, UK facility and offers updates on the ongoing expansion to its Albuquerque, NM facility.

ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced expansion plans to its Glasgow, UK ...

Tel Aviv University scientists say that they can inject CRISPR genetic 'molecular scissors' to shrink tumors by 90%; ...

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics ... technology platforms, research and clinical development plans, and preclinical data and other statements ...

The author is looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing.